M. Luengo et al., BONE-MINERAL DENSITY IN ASTHMATIC-PATIENTS TREATED WITH INHALED CORTICOSTEROIDS - A CASE-CONTROL STUDY, The European respiratory journal, 10(9), 1997, pp. 2110-2113
Recent studies suggest that inhaled corticosteroids can adversely affe
ct bone metabolism, The objective of this study was to evaluate the im
portance of these adverse effects in a case-control study. Bone minera
l density (BMD) was measured in 48 asthmatic adults (15 males and 33 f
emales) treated with inhaled steroids (beclomethasone or budesonide) a
nd in 48 gender and age-matched healthy subjects at baseline and at 2
yrs. Vertebral EMD was measured by dual energy X-ray densitometry. Pat
ients had been treated with a dose of 662+/-278 mu g (range 300-1,000
mu g) of beclomethasone dipropionate or budesonide for more than 1 yr
(mean duration of treatment 10.6 yrs, range 1-16 yrs), Twenty four pat
ients had needed 1-6 short courses of oral steroids and seven had rece
ived oral corticosteroids (mean daily dose 6.2 mg prednisone) for 2-15
yrs more than 4 yrs prior to the BMD measurements. During the follow-
up, 14 patients required 1-3 short courses of oral steroids, There was
no correlation either between inhaled corticosteroid doses or duratio
n of treatment and BMD values, There were no significant differences i
n BMD baseline values between patients and healthy controls, BMD signi
ficantly decreased in both groups at 2 yrs, from 1.08+/-0.19 to 1.05+/
-0.19 g.cm(-2) (p=0.002) in asthmatics versus 1.12+/-0.17 to 1.09+/-0.
18 g.cm(-2) (p=0.008) in controls. There were no significant differenc
es in BMD loss between patients and healthy controls, Furthermore, no
differences were found in bone Loss when pre-and postmenopausal women
were compared with their healthy control counterparts, No differences
in baseline BMD acre found between patients who had received regular o
ral corticosteroid therapy or boaster courses of oral corticosteroids
and those who had not. Inhaled corticosteroid treatment at a mean dose
of 662 mu g.day(-1) and sporadic booster courses of oral corticostero
ids do not further increase bone mass loss with respect to that expect
ed from natural bone mass loss.